Results 171 to 180 of about 10,163 (201)

FcRn Inhibitor Therapies in Neurologic Diseases

CNS Drugs
In the last decade, the landscape of treating autoimmune diseases has evolved with the emergence and approval of novel targeted therapies. Several new biological agents offer selective and target-specific immunotherapy and therefore fewer side effects, such as neonatal Fc receptor (FcRn)-targeting therapy.
Nouf Alfaidi, Salama Karmastaji, Alexandria Matic, Vera Bril   +3 more
semanticscholar   +3 more sources

FcRn: the neonatal Fc receptor comes of age

Nature Reviews Immunology, 2007
The neonatal Fc receptor for IgG (FcRn) has been well characterized in the transfer of passive humoral immunity from a mother to her fetus. In addition, throughout life, FcRn protects IgG from degradation, thereby explaining the long half-life of this class of antibody in the serum. In recent years, it has become clear that FcRn is expressed in various
D. Roopenian, Shreeram Akilesh
semanticscholar   +3 more sources

Albumin Binding to FcRn:  Distinct from the FcRn−IgG Interaction

Biochemistry, 2006
The MHC-related Fc receptor for IgG (FcRn) protects albumin and IgG from degradation by binding both proteins with high affinity at low pH in the acid endosome and diverting both from a lysosomal pathway, returning them to the extracellular compartment.
Chaity, Chaudhury, Charles L, Brooks, Daniel C, Carter, John M, Robinson, Clark L, Anderson   +4 more
openaire   +2 more sources

FcRn-Targeted Mucosal Vaccination against Influenza Virus Infection

The Journal of Immunology, 2021
Abstract The respiratory tract is constantly exposed to various airborne pathogens. Most vaccines against respiratory infections are designed for the parenteral routes of administration; consequently, they provide relatively minimal protection in the respiratory tract.
Susan Park Ochsner, Weizhong Li, Arunraj Mekhemadhom Rajendrakumar, Senthilkumar Palaniyandi, Gyanada Acharya, Xiaoyang Liu, Gefei Wang, Florian Krammer, Meiqing Shi, Wenbin Tuo, C David Pauza, Xiaoping Zhu   +11 more
openaire   +2 more sources

Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier

Nature Communications
The blood-brain barrier (BBB) restricts efficient penetration of systemically delivered therapeutic antibodies into the brain, limiting the development of this class of drugs to treat neurodegenerative diseases.
Julien Lafrance-Vanasse, Shraddha S Sadekar, Yanli Yang, D. B. Yadav, William J. Meilandt, Monica K Wetzel-Smith, Hao Cai, Susan R Crowell, Van Nguyen, Vivian S Lee, Ben Chih, Mandy Kwong, P. Chan, Sara Santagostino, Donna Lee, Shan Chung, Greg A Lazar, James A Ernst, J. Atwal   +18 more
semanticscholar   +1 more source

C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis

Journal of Neurology Neurosurgery & Psychiatry
Background Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity ...
Niklas Huntemann, L. Gerischer, Meret Herdick, Christopher Nelke, Frauke Stascheit, Sarah Hoffmann, Menekşe Öztürk, Christina B. Schroeter, S. Lehnerer, Maike Stein, Charlotte Schubert, C. Schneider-Gold, S. Pfeuffer, Heidrun H. Krämer, F. Konen, T. Skripuletz, M. Pawlitzki, S. Glaubitz, J. Zschüntzsch, V. Scherwietes, A. Totzeck, T. Hagenacker, Sven G Meuth, Andreas Meisel, T. Ruck   +24 more
semanticscholar   +1 more source

Clinical chemistry of human FcRn transgenic mice

Mammalian Genome, 2011
Mice genetically engineered to express human FcRn are valuable models for the evaluation of therapeutic antibodies in the context of human FcRn in vivo. However, only limited clinical chemistry information on these mouse strains is available. Thus, we have compared 30 clinical chemical parameters of C57BL/6J wild-type mice, murine FcRn-knockout mice ...
Stein, Carsten, Kling, Lothar, Proetzel, Gabriele, Roopenian, Derry C, de Angelis, Martin HrabÄ›, Wolf, Eckhard, Rathkolb, Birgit   +6 more
openaire   +3 more sources

Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta‑analysis.

Clinical neurology and neurosurgery (Dutch-Flemish ed. Print)
BACKGROUND Myasthenia gravis (MG) is a chronic, complex autoimmune disorder characterized by the production of autoantibodies that destroy neuromuscular junctions.
Muzamil Akhtar, Mehmood Akhtar, H. Farooqi, Ayesha Maryam, Anam Muzammil, Ummara Hanif, Zoya Athar, Syed Muhammad Hassan, Z. Khan   +8 more
semanticscholar   +1 more source